Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL1/VLDL2 catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study
Primary result · LDL-ApoB100 fractional catabolismResult — go to the resultAfter vs before treatment 0.88 ± 0.37 vs 0.79 ± 0.31 pool/dayAuthors' conclusion
Dapagliflozin does not impair the catabolism of LDL in individuals with type 2 diabetes. It reduces direct catabolism of VLDL1 and increases indirect catabolism of VLDL1 towards VLDL2 and IDL, and of VLDL2 towards IDL, which is closer to normal metabolism.
Study context
- Population
- Individuals with T2Dall completed
- Participants
- 24 individuals
- Comparison
- Dapagliflozin 10 mg/day vs placebo for 6 months
- Dapagliflozinn = 17
- Placebon = 7reference
- Primary endpoint
- Metabolism of ApoB100-containing lipoproteins (LDL-ApoB100 fractional catabolism)
- Follow-up
- 6 months
Methodological detailsdouble-blind, parallel, in vivo kinetic study with stable isotopes
- Double-blind
- Parallel
- In vivo kinetic study with stable isotopes
Primary result
LDL-ApoB100 fractional catabolism · after 6 months
After vs before treatment
0.88 ± 0.37 vs 0.79 ± 0.31 pool/day
P = 0.16
As reported in the abstract
- LDL-ApoB100 fractional catabolism remained unchanged after dapagliflozin treatment
- 0.88 ± 0.37 vs 0.79 ± 0.31 pool/day
Further findings
| Outcome | P value |
|---|---|
| Body weight and HbA1cDapagliflozin vs Placebo | P < 0.001 |
| Body weight and HbA1cDapagliflozin vs Placebo | P = 0.001 |
Plasma TG, LDL-C and ApoB100
- Not significantly modified by dapagliflozin
VLDL1-ApoB100 and VLDL2-ApoB100 catabolism
- Direct catabolism of VLDL1-ApoB100 significantly reduced (pool/day)
- 0.33 ± 0.65 vs 2.37 ± 2.31, p=0.001
- Indirect catabolism of VLDL1-ApoB100 towards VLDL2 and IDL significantly increased (pool/day)
- 2.71 ± 1.51 vs 1.68 ± 1.46, p=0.001
- Catabolism of VLDL2-ApoB100 towards IDL-ApoB100 significantly increased (pool/day)
- 3.57 ± 1.68 vs 2.64 ± 1.90, p=0.049
Safety
- No significant side-effects were observed
Original publication
Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL1/VLDL2 catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study. Diabetologia. Published 17 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →